<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117273</url>
  </required_header>
  <id_info>
    <org_study_id>DR PSE 310</org_study_id>
    <nct_id>NCT00117273</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens</brief_title>
  <official_title>A Prospective, Single-Center, Open-Label, Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duramed Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy,
      reproductive-aged women using three different regimens of oral contraceptives (OCs). Two
      extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days
      followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg
      for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia
      (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date>June 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare differences in hormone patterns (follicle stimulating hormone [FSH], luteinizing hormone [LH], inhibin-B, and estradiol)</measure>
    <time_frame>Before, during and after the 7-day hormone free interval or EE-supplemented interval</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the differences in hormone withdrawal symptoms</measure>
    <time_frame>Before, during and after the 7-day hormone free interval or EE-supplemented interval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare differences in ovarian follicular development</measure>
    <time_frame>Before, during and after the 7-day hormone free interval or EE-supplemented intervals</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]</intervention_name>
    <description>1 tablet daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seasonique (LNG/EE and EE)</intervention_name>
    <description>1 tablet daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Portia (LNG/EE)</intervention_name>
    <description>1 tablet daily x 28 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal

          -  Not pregnant or breastfeeding

          -  Weight &lt;200 lbs

          -  Currently taking oral contraceptives in the standard 28-day regimen for at least two
             months

        Exclusion Criteria:

          -  Any contraindication to the use of oral contraceptives

          -  Pregnancy within the last 3 months

          -  Smoking &gt; 10 cigarettes per day
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duramed Protocol Chair</last_name>
    <role>Study Chair</role>
    <affiliation>Duramed Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mayoclinic.com/health/birth-control/BI99999</url>
    <description>Mayo Clinic - Birth Control Guide</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2005</study_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <name_title>Duramed Protocol Chair</name_title>
    <organization>Duramed Research, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

